Huayao Kangming Biopharma
华药康明
Huayao Kangming Biopharma
Biotech/Healthcare
Huayao Kangming is a high-tech company focused on cancer immunotherapy and the R&D and clinical translation of innovative oncolytic virus therapies. Its pipeline is based on a vaccinia virus platform that offers several advantages, including efficient activation of antitumor immune responses…
Latest round: Series C (2023)
Source: ChinaBulls — chinabulls.com
Last updated 2023-06-01
Funding history
Request access to view this section.
Investors
Request access to view this section.
HQ & website
Request access to view this section.
Tags
Request access to view this section.